


ER α degrader 4

Cat. No.:	HY-144306
Molecular Formula:	C ₄₂ H ₅₈ O ₈
Molecular Weight:	690.91
Target:	Estrogen Receptor/ERR; Apoptosis
Pathway:	Vitamin D Related/Nuclear Receptor; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ER α degrader 4 is an excellent and selective estrogen receptor α (ER α) degrader (IC ₅₀ of 0.31, 0.41 and 0.48 μ M in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ER α degrader 4 has potent inhibitory activity against MCF-7 cell lines. ER α degrader 4 is a potential SERDs candidate for the research of breast cancer ^[1] .														
IC₅₀ & Target	IC ₅₀ : 0.31 μ M (ER α) in MDA-MB-231, 0.41 μ M (ER α) in MCF-7, 0.48 μ M (ER α) in MCF-7/ADR ^[1]														
In Vitro	<p>ERα degrader 4 (compound 16a) (0-10 μM; 48 hours) has the high activity (IC₅₀: 0.31-0.48 μM) against all tested cancer cell lines^[1].</p> <p>ERα degrader 4 (1 μM; 24 hours) increases ERα degradation and relative binding affinity in MCF-7 cancer cells^[1].</p> <p>ERα degrader 4 (0.5, 1 and 2 μM; 24 hours) decreases the number and size of MCF-7 cells colonies at 0.5 μM, and completely suppresses colony formation with 2 μM^[1].</p> <p>ERα degrader 4 (0.5, 1, 2 μM; 24 hours) increases the early-stage apoptosis of MCF-7 cells with a dose-dependent manner^[1].</p> <p>ERα degrader 4 (0.5, 1, 2 μM; 24 hours) can induce the accumulation of reactive oxygen species (ROS) which contributes to the apoptosis of MCF-7 cells^[1].</p> <p>ERα degrader 4 (0.5, 1, 2 μM; 24 hours) induces apoptosis in MCF-7 cancer cells by decreasing the mitochondrial membrane potential^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDA-MB-231, MCF-7, MCF-7/ADR and MCF-10A cells^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Showed the high activity (IC₅₀: 0.31-0.48 μM) against all tested cancer cell lines.</td> </tr> </table> <p>Cell Cycle Analysis</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cells^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0.5, 1, 2 and 3 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> </table>	Cell Line:	MDA-MB-231, MCF-7, MCF-7/ADR and MCF-10A cells ^[1]	Concentration:	0-10 μ M	Incubation Time:	48 hours	Result:	Showed the high activity (IC ₅₀ : 0.31-0.48 μ M) against all tested cancer cell lines.	Cell Line:	MCF-7 cells ^[1]	Concentration:	0.5, 1, 2 and 3 μ M	Incubation Time:	24 hours
Cell Line:	MDA-MB-231, MCF-7, MCF-7/ADR and MCF-10A cells ^[1]														
Concentration:	0-10 μ M														
Incubation Time:	48 hours														
Result:	Showed the high activity (IC ₅₀ : 0.31-0.48 μ M) against all tested cancer cell lines.														
Cell Line:	MCF-7 cells ^[1]														
Concentration:	0.5, 1, 2 and 3 μ M														
Incubation Time:	24 hours														

Result:	Induced cell cycle arrest at G1 phase.
---------	--

Apoptosis Analysis

Cell Line:	MCF-7 cells ^[1]
------------	----------------------------

Concentration:	0.5, 1 and 2 μ M
----------------	----------------------

Incubation Time:	24 hours
------------------	----------

Result:	Increased the early-stage apoptosis of MCF-7 cells with a dose-dependent manner.
---------	--

REFERENCES

[1]. Liang JJ, et al. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment. Eur J Med Chem. 2022;229:114081.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA